|1.||Clayton, Peter T: 3 articles (10/2015 - 04/2005)|
|2.||Danpure, Christopher J: 3 articles (10/2015 - 04/2003)|
|3.||Selhub, Jacob: 3 articles (08/2009 - 04/2003)|
|4.||Mills, Philippa B: 2 articles (10/2015 - 04/2005)|
|5.||Fargue, Sonia: 2 articles (10/2015 - 10/2013)|
|6.||Coburn, Stephen P: 2 articles (01/2015 - 01/2002)|
|7.||Wrenger, Carsten: 2 articles (01/2014 - 01/2009)|
|8.||Talwar, Dinesh: 2 articles (01/2012 - 07/2008)|
|9.||McMillan, Donald C: 2 articles (01/2012 - 07/2008)|
|10.||Gospe, Sidney M: 2 articles (01/2010 - 04/2006)|
03/01/2004 - "Treatment with high-dose pyridoxal phosphate eliminated his seizures."
06/01/2014 - "Median Pyridoxal-phosphate levels in patients with NS compared to patients with primary generalized seizures and community controls were not significantly different. "
03/01/2013 - "Seizures with decreased levels of pyridoxal phosphate in cerebrospinal fluid."
02/01/2002 - "Her seizures are perhaps not solely caused by pyridoxal phosphate deficiency. "
02/01/2002 - "The mechanism by which pyridoxal phosphate controls seizures in this patient is unknown. "
|2.||Infantile Spasms (West Syndrome)
01/01/1987 - "Fifteen (12.7%) among 118 cases of the West syndrome were effectively treated by high-dose pyridoxal phosphate (PAL-P). "
12/01/1998 - "Eighteen children with West syndrome (5-11 months of age) were selected to receive an oral dose of pyridoxal phosphate, (20-50 mg/kg) for 14 d. "
01/01/1987 - "Treatment of the West syndrome with high-dose pyridoxal phosphate."
03/01/2004 - "A successful treatment with pyridoxal phosphate for West syndrome in hypophosphatasia."
01/01/1998 - "Combination therapy consisting of high-dose pyridoxal phosphate (40-50 mg/kg/day) and low-dose synthetic ACTH (0.01 mg/kg/day) was prescribed in 28 children with infantile spasms. "
|3.||Schizophrenia (Dementia Praecox)
01/01/2015 - "Pyridoxal 5 phosphate may have some benefits in reducing the severity of tardive dyskinesia symptoms among individuals with schizophrenia. "
01/01/2015 - "Studies described as randomised controlled trials comparing the effectiveness pyridoxal 5 phosphate with placebo in the treatment of neuroleptic-induced tardive dyskinesia among patients with schizophrenia. "
01/01/1988 - "The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed. "
01/01/2015 - "To determine the effectiveness of pyridoxal 5 phosphate (vitamin B6 or Pyridoxine or Pyridoxal phosphate) in the treatment of neuroleptic-induced tardive dyskinesia among people with schizophrenia and other related psychotic disorders. "
|4.||Movement Disorders (Movement Disorder)
01/01/2015 - "Overall, pyridoxal 5 phosphate produced a significant improvement in tardive dyskinesia symptoms when compared with placebo, assessed by a change in Extrapyramidal Symptoms Rating Scale (ESRS) scores from baseline to the end of the first phase of the included studies (2 RCTs n = 65, RR 19.97, CI 2.87 to 139.19, low quality evidence). "
01/01/2015 - "While there are no known effective treatments for tardive dyskinesia to date, some reports suggest that pyridoxal 5 phosphate may be effective in reducing the severity of tardive dyskinesia symptoms. "
01/01/2015 - "However, the quality of evidence supporting the effectiveness of pyridoxal 5 phosphate in treating tardive dyskinesia is low, based on few studies, short follow-up periods, small sample sizes and inadequate adherence to standardised reporting guidelines for randomised controlled trials among the included studies."
01/01/2015 - "The endpoint tardive dyskinesia score (a measure of its severity) assessed with the ESRS, was significantly lower among participants on pyridoxal 5 phosphate compared to those on placebo (2 RCTs n = 60, MD -4.07, CI -6.36 to -1.79, low quality evidence).It was unclear whether pyridoxal 5 phosphate led to more side effects (n = 65, 2 RCTs, RR 3.97, CI 0.20 to 78.59, low quality evidence) or caused deterioration in tardive dyskinesia symptoms when compared to placebo (n = 65, 2 RCTs, RR 0.16, CI 0.01 to 3.14, low quality evidence). "
01/01/2015 - "Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia."
08/01/1981 - "Gyrate atrophy of the choroid and retina is caused by deficient activity of ornithine ketoacid aminotransferase, a pyridoxal phosphate dependent enzyme. "
07/01/1981 - "It is suggested that the in-vitro examination of the influence of pyridoxal phosphate on ornithine ketoacid transaminase activity in cultured fibroblasts may be useful in ascertaining the efficacy of vitamin B6 treatment in gyrate atrophy. "
|1.||Valproic Acid (Valproate, Semisodium)
|2.||Vitamin B 6
|3.||Ornithine-Oxo-Acid Transaminase (Ornithine Aminotransferase)
|7.||Leucovorin (Folinic Acid)
|9.||Branched-Chain Amino Acids
|2.||Drug Therapy (Chemotherapy)
|5.||Renal Dialysis (Hemodialysis)